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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To establish the effectiveness and safety of different ways of using topical corticosteroids in people with eczema.
B A C K G R O U N D
Description of the condition
Eczema (also called ’atopic dermatitis’ or ’atopic eczema’) is a
chronic inflammatory skin condition, characterised by dry itchy
skin with eczematous lesions, which typically fluctuates between
periods of remission and flares. Eczema often occurs concurrently
with atopic diseases including asthma, allergic rhinitis/hay fever
and food allergy. These diseases share a common pathogenesis,
and frequently present together in the same individual and family.
’Atopy’ refers to the genetic tendency to produce immunoglobu-
lin E (IgE) antibodies in response to small amounts of common
environmental proteins such as pollen, house dust mite, and food
allergens (Stone 2002; Thomsen 2015). Around 30% of people
with eczema develop asthma and 35% develop allergic rhinitis
(Luoma 1983). However, it is known that atopy does not concur-
rently occur in all patients with atopic eczema. In view of this,
there have been recent proposals to use the term ’eczema’ to de-
fine patients both with and without atopy. In agreement with
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the ’Revised nomenclature for allergy for global use’ (Johansson
2004), and for consistency with other Cochrane Reviews evalu-
ating eczema therapies (van Zuuren 2017), we will use the term
’eczema’ throughout the review.
Eczema is a common condition throughout the world affecting ap-
proximately one in five children, and up to 5% of adults (Barbarot
2018; Odhiambo 2009). The incidence of eczema is highest in the
first year of life and can often resolve during childhood (Ban 2018;
Kim 2016). However, a recent review has shown that persistence
into adolescence and early adulthood may be more common than
previously thought, particularly for those with persistent and se-
vere disease or late onset disease (Abuabara 2018).
Eczema can have a significant impact on quality of life (Eckert
2017); and there is a high burden associated with eczema when
compared to other skin diseases (Hay 2014). Both the individ-
ual and their family can be affected by the disease through fac-
tors including disturbed sleep due to itching and scratching, time
off work or school for frequent visits to healthcare professionals,
restrictions to daily activities, and the need to apply daily time-
consuming treatments (Drucker 2016; Eckert 2018).
Clinical features
Eczema may be acute (short and severe) with weeping vesicles on
red, swollen skin, or it may be chronic (long-term) with inflam-
mation, lichenification (thickening of the skin caused by repeated
rubbing or scratching), excoriation (abrasion because of rubbing
or scratching), hyperpigmentation, and exaggerated surface mark-
ings (Weidinger 2016). The typical distribution and type of le-
sions vary during different stages of life and between different eth-
nicities. In infants, the extremities and face are usually affected.
By around two years of age, lesions mainly appear on the limbs,
particularly in the creases of the elbows and knees, as well as the
neck, wrists, and ankles. In adulthood, the lesions can become
more widespread than those seen in childhood (Bieber 2008a).
The severity of eczema can vary enormously, ranging fromdry skin
with the occasional itchy inflamed patch, to involvement of the
whole body with secondary infections. The course of eczema may
also vary from a relapsing-remitting one affecting a few areas re-
currently to a continuous one with prolonged periods of inflamed
skin covering most of the body (Berke 2012). Itching can induce a
vicious cycle of scratching, leading to skin damage, which in turn
causes itchiness-often referred to as the ’itch-scratch cycle’ (Pavlis
2017).
Treatment of eczema
There is currently no cure for eczema, so the treatment goal is
control of the disease using the wide range of treatments avail-
able including emollients (NICE 2007; SIGN 2011). First-line
therapy is the daily application of emollients combined with anti-
inflammatory therapy. The most commonly used anti-inflamma-
tory therapy is topical corticosteroids, but topical calcineurin in-
hibitors are also used. These can be combined with bandages and
phototherapy for those who do not respond sufficiently to topical
treatment alone. Severe eczema may require systemic treatments
such as oral ciclosporin, methotrexate or azathioprine. New bi-
ologic agents such as dupilumab are now available for cases of
eczema that do not respond to other systemic treatments (Snast
2018). Although topical corticosteroids have been the mainstay
of eczema treatment for over 60 years, there are still many unan-
swered questions about how best to use them (Batchelor 2013).
Description of the intervention
Topical corticosteroids were first introduced in the 1950s when
topical hydrocortisone was found to improve various dermatoses
(Sulzberger 1952). Since then, a huge number of topical corticos-
teroids of increased potency have been developed, and are available
in various formulations such as creams and ointments. Mometa-
sone furoate is one of the newer generation of products devel-
oped with the intention of producing a safer potent topical corti-
costeroid (Prakash 1998). Topical corticosteroids are all classified
by their potency from mild through to very potent, although the
classification of potency varies around the world (British National
Formulary 2018;WorldHealthOrganization (WHO)1997). The
choice of potency to be used is based on age, body site to be
treated and severity of eczema. Low- to moderate-potency topical
corticosteroids are usually sufficient for mild eczema and are also
used on sensitive skin such as the face and flexural areas. Potent
or very potent topical corticosteroids are usually used in severe,
thick eczematous plaques over thicker skin sites, such as limbs and
palmoplantar surfaces. The advice is to use topical corticosteroids,
of appropriate potency, once a day until the eczema is controlled,
then ’as required’ (NICE 2007).
Local side effects of topical corticosteroids include the possibility
of skin atrophy (skin thinning), striae (stretch marks) and purpura
(discolouration), whilst systemic side effects include hypothalamic
pituitary axis (HPA) suppression and growth suppression (Callen
2007). Skin thinning and effects on growth and development have
been reported to be themain concerns amongst people using topi-
cal corticosteroids (Li 2017). Side effects of topical corticosteroids
are thought to be rare in usual practice and are more likely to
occur if topical corticosteroids have been used inappropriately,
such as continuous use or if potent corticosteroids are applied to
areas which have high permeability (e.g. eyelids) (Callen 2007;
Nankervis 2016). This inappropriate use could lead to systemic
side effects such as hypothalamic pituitary axis suppression or hy-
perglycaemia (Gilbertson 1998). But despite their relative safety,
concerns and confusion about the use of topical corticosteroids
amongst people with eczema and the healthcare professionals who
treat them are widespread. Negative beliefs about the use of top-
ical corticosteroids are thought to contribute to poor treatment
adherence (Aubert-Wastiaux 2011; Li 2017; Teasdale 2017).
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Topical corticosteroids have traditionally been used reactively (in
response to a worsening of the eczema) to control inflammation
under the skin. They work by reducing skin inflammation by act-
ing on a number of inflammatory pathways. They bind to glu-
cocorticoid intracellular receptors which then results in a number
of anti-inflammatory actions. These include: inhibition of phos-
pholipase A2 activity resulting in reduced production of lipid me-
diators; inhibition of cyclooxygenase induction causing decreased
prostaglandin production; inhibition of nitric oxide synthase pro-
duction; inhibition of cytokine causing suppression of cell-medi-
ated inflammation; inhibition of mast cell activity resulting in de-
creased levels of mast cell inflammatory mediators; and vasocon-
striction (local blood flow reduction) (Ahluwalia 1998).
A number of different ways (or ’strategies’) of using topical corti-
costeroids for treating eczema have been proposed. Proactive use
of topical corticosteroids for two days per week between flares
is thought to help to prevent eczema flares and therefore reduce
the need for more intense periods of topical corticosteroid use to
treat flares which may be associated with an increase in adverse
events (Schmitt 2011). Applying topical corticosteroids to wet
skin after bathing or use of wet wraps may increase penetration
through the skin and increase delivery of the cream or ointment
into the upper layers, thus increasing efficacy of the topical corti-
costeroid (Gonzalez-Lopez 2017;Kohn2016). Topical calcineurin
inhibitors (pimecrolimus or tacrolimus) can be used instead of
topical corticosteroids and a strategy of alternating between these
two treatments may be as effective as using topical corticosteroids
alone, but may reduce the adverse events associated with topical
corticosteroids, such as skin thinning (Broeders 2016).
Some strategies aim to reduce adverse events whilst increasing or
maintaining effectiveness of the topical corticosteroid. Applying
topical corticosteroids once dailymay be as effective as two ormore
times a day but may reduce the likelihood of adverse events oc-
curring (Green 2004). Another strategy Is to use different potency
topical corticosteroids, possibly combined with different duration
of use, such as a more potent topical corticosteroid for a shorter
period compared to milder potency topical corticosteroids for a
longer duration. This reduces the length of time the topical cor-
ticosteroid would be used although more potent topical corticos-
teroids may be associated with increased adverse events (Thomas
2002).
Since topical corticosteroids are used with emollients, other pro-
posed strategies concern the combined use of these two treat-
ments, such as the order in which the treatments are applied
and the optimum time lapse between application of each treat-
ment. Current guidance in the UK from the National Health
Service (NHS) is to apply emollients first then wait for 30 min-
utes before applying the topical corticosteroid for maximal benefit
(NHS 2019). Additionally, different preparations of topical cor-
ticosteroids (e.g. ointments, creams) have been developed to in-
crease the efficacy; and different concentrations (e.g. hydrocorti-
sone 0.5% versus 2.5%). More recently, ’second generation’ once-
daily topical corticosteroids (mometasone furoate and fluticasone
propionate) have been proposed as a safer and effective alternative
to the older topical corticosteroid preparations (Bieber 2008b).
Why it is important to do this review
It is well established that some patients, parents and clinicians
have considerable concerns about using topical corticosteroids for
treating eczema (Charman 2000; Li 2017; Teasdale 2017). As
a result, topical corticosteroids are often under-used in Western
countries, resulting in poorly controlled disease (Lundin 2018).
Conversely, in other areas of theworld, such as India, potent topical
corticosteroid use is often unregulated and patients are able to
obtain these steroids over the counter. Subsequent inappropriate
use of potent topical corticosteroids can lead to an increase in
adverse events (Coondoo 2014).
This situation is exacerbated by the lack of clarity as to how the
different ways of using topical corticosteroids - such as once-a-day
or twice-a-day application, increasing topical corticosteroid po-
tency in response to a flare, or twice-a-week use to proactively pre-
vent flares - affect both effectiveness and safety profile. The British
National Formulary (BNF) provides little reassurance, describ-
ing adrenal suppression as rare but providing no quantification of
other side effects (British National Formulary 2018). Concerns
and uncertainties around topical corticosteroids were highlighted
in the James Lind Alliance Priority Setting Partnership for eczema,
in which the following two topics relating to topical corticosteroid
safety were identified by patients and healthcare professionals as
priority areas for research (Batchelor 2013).
• “What is the best and safest way of using topical
corticosteroids?”
• “What is the long-term safety of topical corticosteroids?”
This comprehensive systematic review is needed to summarise the
available evidence on the effectiveness and safety of different ways
of using topical corticosteroids to support patients and clinicians in
making informed treatment choices. However, since most eczema
trials have a relatively short follow-up, this review will primarily
address the first of these two questions.
The strategies included in this review will refer to different meth-
ods of using topical corticosteroids to improve effectiveness or sa-
fety, or both, and hence achieve the best outcomes for the patients.
A strategy may aim to improve the long-term control of eczema,
for example, in the case of proactive topical corticosteroid treat-
ment. This strategy involves weekly application of topical corti-
costeroid, for two consecutive days, to previously affected or new
sites of eczema, to reduce the risk of flares (Schmitt 2011). Alter-
natively, a strategy such as reducing the frequency of application
may be designed to improve the safety of the drug whilst main-
taining effectiveness (Green 2004; Williams 2007).
This review forms part of a body of work funded by the Na-
tional Institute for Health Research (NIHR) Programme Grants
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for Applied Research (grant no: RP-PG-0216-20007) to develop
an online behavioural intervention to support self-care of eczema
in children, adolescents and young adults (Eczema Care Online,
ECO), and the findings will contribute to development of the in-
tervention by providing data on the best and safest ways to use
topical corticosteroids.
This review will be complemented by another ongoing Cochrane
Review which will incorporate a network meta-analysis: “Topical
treatments for eczema: a network meta-analysis”. The ongoing
Cochrane Review will compare topical corticosteroids to other
topical treatments, such as topical calcineurin inhibitors.
O B J E C T I V E S
To establish the effectiveness and safety of different ways of using
topical corticosteroids in people with eczema.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) where randomisation is
at any level (including cluster and within-participants trials).
Types of participants
Participants of any age and gender with a diagnosis of eczema (also
known as atopic dermatitis or atopic eczema) of any severity by
a healthcare professional, or using established diagnostic criteria
for eczema (e.g. the standardised diagnostic criteria of Hanifin
and Rajka (Hanifin 1980) or the UK Working Party diagnostic
criteria for atopic dermatitis (Williams 1994)).We will also accept
modified versions of standard diagnostic criteria.
Studies which include participants with other types of eczema such
as contact dermatitis, varicose eczema, and seborrhoeic eczema,
or other inflammatory or ’steroid-responsive’ skin conditions such
as psoriasis, will only be included if the trial also includes people
with eczema and the data are reported separately.
Types of interventions
The intervention will be any topical corticosteroid of any prepara-
tion and potency in a trial where one strategy of using the topical
corticosteroid is compared to a different strategy. This will include,
but not necessarily be limited to, the following strategies.
Different strategies for topical corticosteroid use
• Proactive versus reactive topical corticosteroid treatment
(e.g. twice per week versus ’as required’).
• Frequency of application of topical corticosteroid (e.g. once
daily versus twice daily).
• Duration of use of topical corticosteroids for induction of
remission (e.g. short term versus long term).
• Different time of day for applying topical corticosteroids,
and order of application or timing between applications of
topical corticosteroids and emollients (e.g. evening versus
morning, immediately following a bath/shower versus no
guidance).
Different preparations or potencies of topical
corticosteroids
• Different potencies of topical corticosteroids (e.g. mild
versus moderate; stepping up or stepping down potency of
topical corticosteroids).
• Different preparations but the same topical corticosteroid
(e.g. ointment versus cream), including proprietary topical
corticosteroid versus the generic equivalent (e.g. Elocon versus
mometasone furoate 0.1%).
• Different concentrations of topical corticosteroids (e.g.
hydrocortisone 0.5% versus hydrocortisone 2.5%).
Topical corticosteroids alongside other interventions
• Alternating between topical corticosteroids and calcineurin
inhibitors (e.g. topical corticosteroids alone versus alternating
between topical corticosteroids and topical calcineurin
inhibitors).
• Use of topical corticosteroids under occlusion (e.g. with wet
wraps versus no wet wraps).
Other strategies
• Second generation topical corticosteroids (mometasone
furoate and fluticasone propionate) against first generation
topical corticosteroids of the same potency (e.g. mometasone
furoate 0.1% versus betamethasone valerate 0.1%).
• A combination of any of the strategies above (e.g. short
burst of potent topical corticosteroid versus longer duration of
mild topical corticosteroids).
• Any other strategies for using topical corticosteroids not
listed above.
Since the focus of this review is to compare different strategies of
using topical corticosteroids, the following comparisons will be
excluded.
• Topical corticosteroid compared with either no treatment,
vehicle or placebo (unless it is specifically assessing an alternative
regimen such as proactive therapy).
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• Topical corticosteroid compared with another topical
corticosteroid of the same potency and preparation but no
differences in how they are used.
• Topical corticosteroid compared with different topical
treatments such as calcineurin inhibitors or emollients.
• Topical corticosteroid compared with systemic treatments.
• Topical corticosteroid treatment in conjunction with an
eczema treatment used for the most severe cases of eczema as
defined by NICE (i.e. phototherapy and systemic therapy)
(NICE 2018). This is because it will be difficult to detect any
differences in efficacy or safety between the topical
corticosteroids strategies when such treatments are also used.
Types of outcome measures
We will assess both effectiveness and safety to reflect the overall
aim of this review.
The effectiveness outcomes of interest for this review are focused
on the two domains for which the international Harmonizing
Outcome Measures for Eczema (HOME) initiative has recom-
mended core outcome measurement instruments i.e. clinician-re-
ported signs and patient-reported symptoms of eczema (HOME).
There is currently no agreed standardised timing for effectiveness
outcome assessments for eczema trials. Therefore, to assess treat-
ment effects in a consistent way, we will focus on short-term ef-
fectiveness outcomes reported between one and four weeks (tak-
ing the earliest available time point within that range), medium-
term effectiveness outcomes between 12 and 16 weeks (taking the
closest time point to 12 weeks), and long-term effectiveness as the
longest time point greater than 16 weeks.
We will also report outcomes at baseline, end of treatment, and
end of follow-up regardless of timing. We will attempt to pool
data at similar time points where possible.
Because many different instruments are used to assess effectiveness
of treatments for eczema (Schmitt 2007), we will use a hierarchical
approach in which we will initially extract data from one instru-
ment per outcome based on the priority order described below.
However, we will also make a note of other instruments reported,
and data from other lower priority instruments may also be ex-
tracted tomaximize our ability to summarise data in pooled analy-
ses. Where possible, we will also compare the effect sizes calculated
in this review against the minimal clinically important differences
(MCID) from the literature.
Throughout this review, we will use the term ’effectiveness’ to
describe both ’efficacy’ and ’effectiveness’. In many trials it is likely
to be unclear whether the trial is primarily assessing efficacy or
effectiveness and we would prefer to avoid making inappropriate
judgements.
Safety outcomes of interest reflect the side effects of topical corti-
costeroids. We define ’relevant’ adverse events as those previously
identified as being of particular concern to patients (Li 2017), the
side effects listed in the Summary of Product Characteristics for
topical corticosteroids used to treat eczema, and original data sub-
missions from the Eczema Priority Setting Partnership, outlining
patients’ and clinicians’ concerns about the safety of topical corti-
costeroids (Batchelor 2013).We will report data on individual rel-
evant adverse events and their relatedness to the study drug where
available. Where appropriate, the total number of relevant adverse
events per treatment group will be reported to allow pooling of
data. We will present safety data for the treatment and follow-up
periods separately where possible. Where outcomes are assessed
during post-treatment follow-up, we will only include data where
participants are retained in their randomised groups. We will not
use long-term safety data from crossover or within-participant tri-
als due to the high likelihood of contamination.
For safety data, wewill report adverse events at the endof treatment
and the end of follow-up (where specified).
Primary outcomes
Twoprimary outcomes are included - safety and effectiveness (clin-
ician-reported signs of eczema) - to reflect the overall aim of this
review.
• Changes in clinician-reported signs of eczema
(effectiveness). We will extract data based on the following
priority order of instruments.
◦ Eczema Area and Severity Index (EASI) - this is the
HOME recommended core outcome measurement instrument
for clinician-reported signs of eczema (Hanifin 2001;Schmitt
2014).
◦ Objective SCORing Atopic Dermatitis
(ObjSCORAD) - measures similar aspects of the disease to EASI
(Kunz 1997;Oranje 2007).
◦ SCORing Atopic Dermatitis (SCORAD) - most
commonly used instrument in eczema trials, comprising
objective SCORAD plus itch and sleep loss (Kunz 1997;Oranje
2007)
◦ Six Area, Six Sign Atopic Dermatitis (SASSAD)
severity score (Berth-Jones 1996).
◦ Three Item Severity score (TIS) (Oranje
2007;Willemsen 2009;Wolkerstorfer 1999).
◦ Investigator Global Assessment (IGA) - no validated
instrument and little consistency between trials but commonly
included (Futamura 2016).
◦ Any other instruments.
• Number of relevant local adverse events (safety). This
will include skin thinning, striae, telangiectasia, aging/wrinkling,
changes in skin colour, sensitisation, skin bleaching, worsening or
induction of acne, skin infections, folliculitis, perioral/periocular
dermatitis, and application site reactions such as burning
sensation/stinging. In our analyses, we will primarily focus on
the number of participants with at least one adverse event.
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Secondary outcomes
• Patient-reported symptoms of eczema (effectiveness).
Data will be extracted based on the following priority order of
instruments.
◦ Patient-Oriented Eczema Measure (POEM) -
recommended core instrument by HOME for the patient-
reported symptoms of eczema (Charman 2004;Spuls 2017).
◦ Patient-Oriented SCORAD (PO-SCORAD)
(Vourc’h-Jourdain 2009).
◦ Sleep and itch scales, as measured by Visual Analogue
Scales (VAS) or Numerical Rating Scales (NRS).
◦ Self-Administered EASI (SA-EASI) (Housman 2002).
◦ Patient Global Assessment (PGA) - no validated
instrument and little consistency between trials.
◦ Any other instruments.
• Number of relevant systemic adverse events (safety).
This will include bone problems, impact on growth and
development, effects on endocrine system, eye problems, and
cancer. In our analyses, we will primarily focus on the number of
participants with at least one adverse event.
Search methods for identification of studies
We aim to identify all relevant randomised controlled trials (RCTs)
regardless of language or publication status (published, unpub-
lished, in press, or in progress).
Electronic searches
The Cochrane Skin Information Specialist will search the follow-
ing databases for relevant trials with no restriction by date.
• the Cochrane Skin Specialised Register;
• the Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library;
• MEDLINE via Ovid (from 1946 onwards);
• Embase via Ovid (from 1974 onwards);
• the GREAT database (Global Resource for EczemA Trials
(Centre of Evidence Based Dermatology);
www.greatdatabase.org.uk).
The Information Specialist has devised a draft search strategy for
RCTs for MEDLINE (Ovid), which is displayed in Appendix 1.
We will use this as the basis for search strategies for the other
databases listed.
Trial registers
We (EA, JH) will search the following trial registers using the
search terms ’eczema’ and ’atopic dermatitis’.
• the ISRCTN register (www.isrctn.com);
• ClinicalTrials.gov ( www.clinicaltrials.gov);
• the Australian New Zealand Clinical Trials Registry (
www.anzctr.org.au);
• the World Health Organization International Clinical Trials
Registry Platform ( ICTRP) ( apps.who.int/trialsearch/); and
• the EU Clinical Trials Register (
www.clinicaltrialsregister.eu).
Searching other resources
Searching reference lists
We will check the bibliographies of included studies and any rele-
vant systematic reviews identified for further references to relevant
trials.
Correspondence with trialists
We will contact trialists for clarification and further data if trial
reports are unclear.
Adverse effects
We will not perform a separate search for adverse effects of the
target interventions. We will consider adverse effects described in
included studies only.
Data collection and analysis
We will use Covidence systematic review software to screen and
manage the references, and to record the data extracted from the in-
cluded studies. The software will also automatically create a study
flow diagram (PRISMA) for us to include in the review (Liberati
2009).
Selection of studies
Two review authors (EA, JH) will independently screen the titles
and abstracts of each record identified in the searches. If a study
meets our inclusion criteria, we will analyse the full text to confirm
its inclusion. Any disagreementwith be resolved by a third reviewer
(JRC, KST or HCW). We will record reasons for exclusions in
the ’Characteristics of excluded studies’ table. We will present the
process of trial selection in a PRISMA flow diagram (Liberati
2009).
Data extraction and management
Two review authors (EA, JH) will independently extract data from
each included study using a data extraction form. We will pilot
and modify the form, as necessary. The following data will be
extracted.
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• Study population (e.g. inclusion criteria, setting/country,
severity of eczema, age, gender, ethnicity)
• Study methods (e.g. study design, blinding methods,
funding source)
• Interventions and comparators (e.g. treatment name,
potency, frequency of use)
• Primary and secondary outcomes (including time points -
both during treatment and during follow-up)
We will enter study characteristics into a ’Characteristics of in-
cluded studies’ table; and we will analyse or narratively describe
extracted outcome data. We will resolve any disagreements during
the data extraction phase through discussion with a third author
(JRC, KST, or HCW).
Wewill includemultiple reports of a trial but will choose a primary
reference and list the others as secondary references.
We will also extract study characteristics for ongoing trials to pro-
duce a ’Characteristics of ongoing studies’ table. We will do the
same for ’Studies awaiting classification’ where there is not enough
information available for us to include or exclude the trial in the
review.
Assessment of risk of bias in included studies
Two authors (EA, JH) will independently assess the risk of bias of
each included study using theCochrane ’Risk of bias’ tool (Higgins
2011). The following domains will be assessed.
• Selection bias (random sequence generation and allocation
concealment)
• Performance bias (blinding of participants and study
personnel)
• Detection bias (blinding of outcome assessment)
• Attrition bias (completeness of data, missing data and losses
to follow-up, intention to treat principle)
• Reporting bias (selective reporting of outcomes, assessed via
comparing with the study’s protocol or clinical trial register entry)
• Other bias (including design-specific risks of bias, baseline
imbalance, contamination, fraud, selective reporting of
subgroups)
Each domain will be assessed as low, unclear or high risk of bias.
Disagreements will be resolved via discussion with a third author
(JRC, KST or HCW). We will present a ’Risk of bias’ graph and
’Risk of bias’ summary figure in the review.
Measures of treatment effect
Wewill report dichotomous data as risk ratios (RR)with associated
95% confidence intervals (CI). Continuous data will be reported
as mean differences (MD) with associated 95% CIs where the
same scale is used to measure an outcome. Where appropriate, we
may consider using a standardised mean difference (SMD) and
associated 95%CI when different instruments are used tomeasure
effectiveness outcomes (i.e. clinician-reported signs and patient-
reported symptoms).
For adverse event data, we will focus on analysing the number
of participants with at least one adverse event, and hence we will
report RR.However, in some studies the number of events per arm
may only be reported and it will not be clear if multiple adverse
events occurred within the same individual. For these studies, we
will contact the authors to request data in the format of ’number
of participants with at least one adverse event’. If we are unable
to obtain these data, we will analyse these data as count data,
following guidance from the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011), and produce rate ratios
instead of RR. Where studies report time-to-flare data based on a
measure of effectiveness (e.g. EASI), we shall extract hazard ratios
(HR) from the study reports.
Unit of analysis issues
The unit of analysis will primarily be the individual participant.
If only count data is available for adverse events, we will analyse
the number of events over time and calculate rate ratios. We will
only meta-analyse cluster RCTs with parallel RCTs if the data
reported in the trial publication has been correctly analysed, taking
into account the number of clusters. If appropriate, we may try
to estimate the intracluster correlation coefficient to enable us to
include the trial in the meta-analysis (Higgins 2011).
For within-participant trials, we will extract paired data from the
study report and analyse separately to parallel RCTs. If paired data
are not available, we will attempt to estimate the paired data using
appropriate methods and guidance from the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011; Hirji 2011).
If this is not possible, we will only use data from the first part of
the study in cross-over trials, or narratively describe the results.
For within-participant trials where body parts receive different
interventions, we will not extract data on outcomes which affect
the whole body (e.g. systemic adverse events), as it will not be
possible to determine which treatment caused the event.
For studies which include multiple intervention groups, we will
either analyse each intervention group versus a comparator in a
separate analysis, or combine groups to create a single pair-wise
comparison, if clinically appropriate (Higgins 2011).
Dealing with missing data
Where possible we will conduct an intention-to-treat analysis, in-
cluding all randomised participants where data is provided. If data
is missing, we will contact study authors and produce a table in the
review detailing such contact (e.g. dates, information requested,
whether they replied).Wewill conduct sensitivity analyses, remov-
ing studies at high risk of attrition bias and will also consider attri-
tion bias when undertaking our quality assessments (Schünemann
2013). For continuous data, we will attempt to calculate any miss-
ing statistics (e.g. standard deviations) using themethods described
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in theCochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).
Assessment of heterogeneity
When pooling studies in a meta-analysis, we will consider any
methodological and clinical differences between studies, and only
include studies in the same meta-analysis where it is considered
appropriate. We will assess heterogeneity through forest plot in-
spection and the I² statistic using the thresholds defined in the
Cochrane Handbook for Systematic Reviews of Interventions: 0% to
40%might not be important; 30% to 60%may represent moder-
ate heterogeneity; 50% to 90% may represent substantial hetero-
geneity; and 75% to 100% represents considerable heterogeneity
(Higgins 2011). If we identify substantial or considerable statisti-
cal heterogeneity, we will attempt to determine reasons by exam-
ining the study characteristics and performing subgroup analyses
where appropriate.
Assessment of reporting biases
If we include 10 ormore studies in ameta-analysis, wewill produce
a funnel plot to explore publication bias (Sterne 2011). We will
describe narratively suspected reporting biases and their potential
effects on the overall results and conclusions.
Data synthesis
We will narratively synthesise outcome data and will conduct
meta-analysis (if appropriate) in Review Manager 5, using the
random-effects model (Review Manager 2014). We will use the
generic inverse variance model to analyse count data (rate ratios)
and may use it to compare studies that have presented a group
difference, or have adjusted analysis only. We will present effect
estimates, with 95% confidence intervals and associated I² statistic
and P value, for all pooled synthesis. For dichotomous outcomes,
if statistical evidence of an effect is reported we will calculate an
associated number needed to treat for an additional beneficial out-
come (with associated 95% confidence intervals).
Subgroup analysis and investigation of heterogeneity
We plan the following subgroup analyses.
• Children versus adults
• Anatomical site e.g. topical corticosteroid applied to
sensitive sites (face/genitals) versus other body sites
• Baseline severity of eczema (mild disease versus moderate
and severe, as specified in the trial report)
If there is substantial statistical heterogeneity (via forest plot in-
spection and using the I² statistic), additional clinical andmethod-
ological differences will be investigated. Clinical differences may
include filaggrin (FLG) mutation status, age sub-groups of chil-
dren (0 to 4, 5 to 11, and 11+ years), chronic versus acute disease,
and body surface area affected.
Sensitivity analysis
If possible, we will perform a sensitivity analysis removing studies
at high risk of bias from the meta-analysis. We will also perform
sensitivity analyses where assumptions have been made or data
imputed.
’Summary of findings’ tables and GRADE assessments
We will create ’Summary of findings’ tables for our main com-
parisons. We have selected the following four most relevant and
important comparisons, from both clinician and patient perspec-
tives, to be included in the ’Summary of findings’ tables.
1. Proactive versus reactive topical corticosteroid treatment
(e.g. twice per week versus ’as required’)
2. Frequency of application of topical corticosteroid (e.g. once
daily versus twice daily)
3. Duration of use of topical corticosteroids for induction of
remission (e.g. short term versus long term)
4. Different potencies of topical corticosteroids (e.g. mild
versus moderate; stepping up or stepping down topical
corticosteroids)
We will include both primary outcomes and secondary outcomes
in each ’Summary of findings’ table. We will use the GRADE ap-
proach to assess the certainty of evidence for each primary and sec-
ondary outcome for our main comparisons. GRADE includes the
assessment of five factors: study limitations (risk of bias); incon-
sistency of results; indirectness of evidence; imprecision; and pub-
lication bias (Schünemann 2013). Each outcome can be down-
graded by one or two levels for each domain, and we will class
the overall certainty as high, moderate, low or very low. We will
use GRADEpro to create our ’Summary of findings’ tables and
undertake our GRADE assessments (GRADEpro GDT).
A C K N OW L E D G E M E N T S
We would like to thank Douglas Grindlay for his input into this
protocol.
We would also like to thank Liz Doney, the information specialist
at Cochrane Skin, for her assistance in drafting the search strategy.
The Cochrane Skin editorial base wishes to thank Ching-Chi Chi,
Cochrane Dermatology Editor; Toby Lasserson, who provided
methodological comment; the clinical referee, YikWeng Yew; and
Jason Elliot-Smith, who copy-edited the protocol.
8Different strategies for using topical corticosteroids in people with eczema (Protocol)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
R E F E R E N C E S
Additional references
Abuabara 2018
Abuabara K, Yu AM, Okhovat JP, Allen IE, Langan SM.
The prevalence of atopic dermatitis beyond childhood: A
systematic review and meta-analysis of longitudinal studies.
Allergy 2018;73(3):696–704.
Ahluwalia 1998
Ahluwalia A. Topical glucocorticoids and the skin-
mechanisms of action: an update. Mediators of Inflammation
1998;7(3):183–93.
Aubert-Wastiaux 2011
Aubert-Wastiaux H, Moret L, Le Rhun A, Fontenoy AM,
Nguyen JM, Leux C, et al. Topical corticosteroid phobia
in atopic dermatitis: a study of its nature, origins and
frequency. British Journal of Dermatology 2011;165(4):
808–14.
Ban 2018
Ban L, Langan SM, Abuabara K, Thomas KS, Abdul
Sultan A, Sach T, et al. Incidence and sociodemographic
characteristics of eczema diagnosis in children: a cohort
study. Journal of Allergy and Clinical Immunology 2018;141
(5):1927–9. DOI: 10.1016/j.jaci.2017.12.997
Barbarot 2018
Barbarot S, Auziere S, Gadkari A, Girolomoni G, Puig L,
Simpson EL, et al. Epidemiology of atopic dermatitis in
adults: Results from an international survey. Allergy 2018;
73(6):1284–93. DOI: 10.1111/all.13401
Batchelor 2013
Batchelor JM, Ridd MJ, Clarke T, Ahmed A, Cox M,
Crowe S, et al. The Eczema Priority Setting Partnership:
a collaboration between patients, carers, clinicians and
researchers to identify and prioritize important research
questions for the treatment of eczema. British Journal of
Dermatology 2013;168:577–82.
Berke 2012
Berke R, Singh A, Guralnick M. Atopic dermatitis: an
overview. American Family Physician 2012;86(1):35–42.
Berth-Jones 1996
Berth-Jones J. Six area, six sign atopic dermatitis (SASSAD)
severity score: a simple system for monitoring disease
activity in atopic dermatitis. British Journal of Dermatology
1996;135 Suppl 48:25–30.
Bieber 2008a
Bieber T. Atopic dermatitis. New England Journal of
Medicine 2008;358(14):1483–94.
Bieber 2008b
Bieber T. Atopic and contact dermatitis. In: Rich R,
Fleisher T, Shearer W, Schroeder H, Frew A, Weyand C
editor(s). Clinical Immunology: Principles and Practice. 3rd
Edition. St Louis, MO: Mosby, 2008:667–80.
British National Formulary 2018
Joint Formulary Committee. British National Formulary
(online). www.bnf.nice.org.uk (accessed 28 June 2018).
Broeders 2016
Broeders JA, Ahmed Ali U, Fischer G. Systematic review
and meta-analysis of randomized clinical trials (RCTs)
comparing topical calcineurin inhibitors with topical
corticosteroids for atopic dermatitis: A 15-year experience.
Journal of the American Academy of Dermatology 2016;75(2):
410–9.e3.
Callen 2007
Callen J, Chamlin S, Eichenfield LF, Ellis C, Girardi M,
Goldfarb M, et al. A systematic review of the safety of
topical therapies for atopic dermatitis. British Journal of
Dermatology 2007;156(2):203–21.
Charman 2000
Charman CR, Morris AD, Williams HC. Topical
corticosteroid phobia in patients with atopic eczema. British
Journal of Dermatology 2000;142(5):931–6.
Charman 2004
Charman CR, Venn AJ, Williams HC. The patient-oriented
eczema measure: development and initial validation of a
new tool for measuring atopic eczema severity from the
patients’ perspective. Archives of Dermatology 2004;140
(12):1513–9.
Coondoo 2014
Coondoo A. Topical corticosteroid misuse: the Indian
scenario. Indian Journal of Dermatology 2014;59(5):451–5.
Covidence [Computer program]
Veritas Health Innovation. Covidence. Melbourne,
Australia: Veritas Health Innovation, 2017.
Drucker 2016
Drucker AM, Wang AR, Qureshi AA. Research gaps in
quality of life and economic burden of atopic dermatitis:
the National Eczema Association burden of disease audit.
JAMA Dermatology 2016;152(8):873–4.
Eckert 2017
Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P,
Gelfand JM. Impact of atopic dermatitis on health-related
quality of life and productivity in adults in the United
States: An analysis using the National Health and Wellness
Survey. Journal of the American Academy of Dermatology
2017;77(2):274-9. e3.
Eckert 2018
Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P,
Gelfand JM. The burden of atopic dermatitis in US adults:
Health care resource utilization data from the 2013 National
Health and Wellness Survey. Journal of the American
Academy of Dermatology 2018;78(1):54-61. e1.
Futamura 2016
Futamura M, Leshem YA, Thomas KS, Nankervis H,
Williams HC, Simpson EL. A systematic review of
Investigator Global Assessment (IGA) in atopic dermatitis
(AD) trials: Many options, no standards. Journal of the
American Academy of Dermatology 2016;74(2):288–94.
9Different strategies for using topical corticosteroids in people with eczema (Protocol)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Gilbertson 1998
Gilbertson EO, Spellman MC, Piacquadio DJ, Mulford
MI. Super potent topical corticosteroid use associated with
adrenal suppression: clinical considerations. Journal of the
American Academy of Dermatology 1998;38(2 Pt 2):318–21.
Gonzalez-Lopez 2017
Gonzalez-Lopez G, Ceballos-Rodriguez RM, Gonzalez-
Lopez JJ, Feito Rodriguez M, Herranz-Pinto P. Efficacy
and safety of wet wrap therapy for patients with atopic
dermatitis: a systematic review and meta-analysis. British
Journal of Dermatology 2017;177(3):688–95.
GRADEpro GDT [Computer program]
McMaster University (developed by Evidence Prime).
GRADEpro GDT. Hamilton (ON): McMaster University
(developed by Evidence Prime), 2015.
Green 2004
Green C, Colquitt JL, Kirby J, Davidson P, Payne E. Clinical
and cost-effectiveness of once-daily versus more frequent use
of same potency topical corticosteroids for atopic eczema:
a systematic review and economic evaluation. Health
Technology Assessment 2004;8(47):iii,iv, 1-120.
Hanifin 1980
Hanifin JM, Rajka G. Diagnostic features of atopic
dermatitis. Acta Dermato-venereologica 1980;92:44–7.
Hanifin 2001
Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ,
Graeber M. The eczema area and severity index (EASI):
assessment of reliability in atopic dermatitis. EASI Evaluator
Group. Experimental Dermatology 2001;10(1):11–8.
Hay 2014
Hay RJ, Williams NE,Williams HC, Bolliger IW, Dellavalle
RP, Margolis DJ, et al. The global burden of skin disease
in 2010: an analysis of the prevalence and impact of skin
conditions. Journal of Investigative Dermatology 2014;134
(6):1527–34.
Higgins 2011
Higgins JP, Green S, editor(s). Cochrane Handbook
for Systematic Reviews of Interventions Version 5.1.0
(updated March 2011). The Cochrane Collaboration,
2011. Available from handbook.cochrane.org.
Hirji 2011
Hirji KF, FagerlandMW. Calculating unreported confidence
intervals for paired data. BMCMedical Research Methodology
2011;11:66.
HOME
Harmonising Outcome Measures for Eczema (HOME).
www.homeforeczema.org/ (accessed prior to 03 May 2018).
Housman 2002
Housman TS, Patel MJ, Camacho F, Feldman SR, Fleischer
AB Jr, Balkrishnan R. Use of the Self-Administered Eczema
Area and Severity Index by parent caregivers: results of a
validation study. British Journal of Dermatology 2002;147
(6):1192–8.
Johansson 2004
Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier
BQ, Lockey RF, et al. Revised nomenclature for allergy for
global use: Report of the Nomenclature Review Committee
of the World Allergy Organization October 2003. Journal
of Allergy and Clinical Immunology 2004;113(5):832–6.
[PUBMED: 15131563]
Kim 2016
Kim JP, Chao LX, Simpson EL, Silverberg JI. Persistence
of atopic dermatitis (AD): A systematic review and meta-
analysis. Journal of American Academy of Dermatology 2016;
75(4):681–687.e11.
Kohn 2016
Kohn LL, Kang Y, Antaya RJ. A randomized, controlled
trial comparing topical steroid application to wet versus dry
skin in children with atopic dermatitis (AD). Journal of the
American Academy of Dermatology 2016;75(2):306–11.
Kunz 1997
Kunz B, Oranje AP, Labreze L, Stalder JF, Ring J, Taieb A.
Clinical validation and guidelines for the SCORAD index:
consensus report of the European Task Force on Atopic
Dermatitis. Dermatology 1997;195(1):10–9.
Li 2017
Li AW, Yin ES, Antaya RJ. Topical corticosteroid phobia in
atopic dermatitis: A systematic review. JAMA Dermatology
2017;153(10):1036–42.
Liberati 2009
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC,
Ioannidis JP, et al. The PRISMA statement for reporting
systematic reviews and meta-analyses of studies that evaluate
health care interventions: explanation and elaboration.
PLoS Medicine 2009;6(7):e1000100.
Lundin 2018
Lundin S, Wahlgren CF, Bergstrom A, Johansson EK,
Dahlen E, Andersson N, et al. Use of emollients and topical
glucocorticoids among adolescents with eczema - data from
the population-based birth cohort BAMSE. British Journal
of Dermatology 2018;179(3):709–16.
Luoma 1983
Luoma R, Koivikko A, Viander M. Development of asthma,
allergic rhinitis and atopic dermatitis by the age of five years.
A prospective study of 543 newborns. Allergy 1983;38(5):
339-46. [PUBMED: 6614406]
Nankervis 2016
Nankervis H, Thomas KS, Delamere FM, Barbarot S,
Rogers NK, Williams HC. Scoping systematic review of
treatments for eczema. Southampton (UK): NIHR Journals
Library. Programme Grants for Applied Research, 2016.
NHS 2019
National Health Service (NHS). Topical corticosteroids.
www.nhs.uk/conditions/topical-steroids/ (accessed 05
February 2019).
NICE 2007
NICE. Clinical guideline [CG57]. Atopic eczema in under
12s: diagnosis and management 2007. www.nice.org.uk/
Guidance/CG57 (accessed prior to 03 May 2018).
10Different strategies for using topical corticosteroids in people with eczema (Protocol)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NICE 2018
NICE. Eczema overview. Treating atopic eczema in children
aged 12 and under. pathways.nice.org.uk/pathways/eczema
(accessed 26 July 2018).
Odhiambo 2009
Odhiambo JA, Williams HC, Clayton TO, Robertson
CF, Asher MI, ISAAC Phase Three Study Group. Global
variations in prevalence of eczema symptoms in children
from ISAAC Phase Three. Journal of Allergy and Clinical
Immunology 2009;124(6):1251–1258.e23.
Oranje 2007
Oranje AP, Glazenburg EJ, Wolkerstorfer A, de Waard-
van der Spek FB. Practical issues on interpretation of
scoring atopic dermatitis: the SCORAD index, objective
SCORAD and the three-item severity score. British Journal
of Dermatology 2007;157(4):645–8.
Pavlis 2017
Pavlis J, Yosipovitch G. Management of itch in atopic
dermatitis. American Journal of Clinical Dermatology 2017
[Epub ahead of print]. DOI: 10.1007/s40257-017-0335-4.
Prakash 1998
Prakash A, Benfield P. Topical mometasone. A review of
its pharmacological properties and therapeutic use in the
treatment of dermatological disorders. Drugs 1998;55(1):
145–63.
Review Manager 2014 [Computer program]
Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager 5 (RevMan 5). Version 5.3. Copenhagen:
Nordic Cochrane Centre, The Cochrane Collaboration,
2014.
Schmitt 2007
Schmitt J, Langan S, Williams HC, European Dermato-
Epidemiology Network. What are the best outcome
measurements for atopic eczema? A systematic review.
Journal of Allergy and Clinical Immunology 2007;120(6):
1389–98.
Schmitt 2011
Schmitt J, Von Kobyletzki L, Svensson A, Apfelbacher
C. Efficacy and tolerability of proactive treatment with
topical corticosteroids and calcineurin inhibitors for atopic
eczema: Systematic review and meta-analysis of randomized
controlled trials. British Journal of Dermatology 2011;164
(2):415–28.
Schmitt 2014
Schmitt J, Spuls PI, Thomas KS, Simpson E, Furue M,
Deckert S, et al. The Harmonising Outcome Measures for
Eczema (HOME) statement to assess clinical signs of atopic
eczema in trials. Journal of Allergy and Clinical Immunology
2014;134(4):800–7.
Schünemann 2013
Schünemann H, Brozek J, Oxman A, editors. GRADE
handbook for grading quality of evidence and
strength of recommendation. Updated October 2013.
www.guidelinedevelopment.org/handbook. The GRADE
Working Group. Available from:, (accessed prior to 03 May
2018).
SIGN 2011
SIGN (Scottish Intercollegiate Guidelines Network).
Management of atopic eczema in primary care 2011.
www.sign.ac.uk (accessed prior to 03 May 2018).
Snast 2018
Snast I, Reiter O, Hodak E, Friedland R, Mimouni D,
Leshem YA. Are Biologics Efficacious in Atopic Dermatitis?
A Systematic Review and Meta-Analysis. American Journal
of Clinical Dermatology 2018;19(2):145–65.
Spuls 2017
Spuls PI, Gerbens LAA, Simpson E, Apfelbacher CJ,
Chalmers JR, Thomas KS, et al. Patient-Oriented Eczema
Measure (POEM), a core instrument to measure symptoms
in clinical trials: a Harmonising Outcome Measures for
Eczema (HOME) statement. British Journal of Dermatology
2017;176(4):979–84.
Sterne 2011
Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau
J, et al. Recommendations for examining and interpreting
funnel plot asymmetry in meta-analyses of randomised
controlled trials. BMJ 2011;343:d4002.
Stone 2002
Stone KD. Atopic diseases of childhood. Current Opinion
in Pediatrics 2002;14(5):634–46. [PUBMED: 12352260]
Sulzberger 1952
Sulzberger MB, Witten VH. The effect of topically applied
compound F in selected dermatoses. Journal of Investigative
Dermatology 1952;19(2):101–2.
Teasdale 2017
Teasdale EJ, Muller I, Santer M. Carers’ views of topical
corticosteroid use in childhood eczema: a qualitative study
of online discussion forums. British Journal of Dermatology
2017;176(6):1500–7.
Thomas 2002
Thomas KS, Armstrong S, Avery A, Po AL, O’Neill C,
Young S, et al. Randomised controlled trial of short bursts
of a potent topical corticosteroid versus prolonged use of a
mild preparation for children with mild or moderate atopic
eczema. BMJ 2002;324(7340):768.
Thomsen 2015
Thomsen SF. Epidemiology and natural history of atopic
diseases. European Clinical Respiratory Journal 2015;2(1):
24642. [PUBMED: 26557262]
van Zuuren 2017
van Zuuren EJ, Fedorowicz Z, Christensen R, Lavrijsen
A, Arents BWM. Emollients and moisturisers for eczema.
Cochrane Database of Systematic Reviews 2017, Issue 2.
DOI: 10.1002/14651858.CD012119.pub2
Vourc’h-Jourdain 2009
Vourc’h-Jourdain M, Barbarot S, Taieb A, Diepgen T,
Ambonati M, Durosier V, et al. Patient-oriented SCORAD:
a self-assessment score in atopic dermatitis. A preliminary
feasibility study. Dermatology 2009;218(3):246–51.
11Different strategies for using topical corticosteroids in people with eczema (Protocol)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Weidinger 2016
Weidinger S, Novak N. Atopic dermatitis. Lancet 2016;387
(10023):1109–22.
Willemsen 2009
Willemsen MG, van Valburg RW, Dirven-Meijer PC,
Oranje AP, van der Wouden JC, Moed H. Determining
the severity of atopic dermatitis in children presenting in
general practice: an easy and fast method. Dermatology
Research and Practice 2009;2009:357046.
Williams 1994
Williams HC, Burney PG, Hay RJ, Archer CB, Shipley
MJ, Hunter JJ, et al. The U.K. Working Party’s Diagnostic
Criteria for Atopic Dermatitis. I. Derivation of a minimum
set of discriminators for atopic dermatitis. British Journal of
Dermatology 1994;131(3):383–96.
Williams 2007
Williams HC. Established corticosteroid creams should be
applied only once daily in patients with atopic eczema. BMJ
2007;334(7606):1272.
Wolkerstorfer 1999
Wolkerstorfer A, de Waard van der Spek FB, Glazenburg
EJ, Mulder PG, Oranje AP. Scoring the severity of atopic
dermatitis: three item severity score as a rough system for
daily practice and as a pre-screening tool for studies. Acta
Dermato-venereologica 1999;79(5):356–9.
World Health Organization (WHO) 1997
World Health Organization (WHO). WHO model
prescribing information: drugs used in skin diseases.
www,apps.who.int/medicinedocs/en/d/Jh2918e/32.html
(accessed 6 July 2018).
∗ Indicates the major publication for the study
A P P E N D I C E S
Appendix 1. Draft MEDLINE (Ovid) search strategy
1. exp Eczema/ or eczema$.ti,ab.
2. exp Dermatitis, Atopic/
3. neurodermatitis.ti,ab. or exp Neurodermatitis/
4. exp Dermatitis/ or dermatitis.ti,ab.
5. besnier$ prurigo.ti,ab.
6. prurigo diathesique.ti,ab.
7. or/1-6
8. (topical$ adj3 corticosteroid$).ti,ab.
9. (topical$ adj3 steroid$).ti,ab.
10. (topical$ adj3 corticoid$).ti,ab.
11. (topical$ adj3 glucocorticoid$).ti,ab.
12. exp Desonide/
13. desonide.mp.
14. alclometasone.mp.
15. amcinonide.mp.
16. exp Beclomethasone/
17. (beclometasone or beclomethasone).mp.
18. exp Betamethasone/
19. Betamethasone.mp.
20. budesonide.mp. or exp Budesonide/
21. clobetasol$.mp. or exp Clobetasol/
22. clobetasone$.mp.
23. clocortolone.mp.
24. (exp Cortisone/ or cortisone.ti,ab.) and (exp Administration, Topical/ or exp Ointments/ or Dermatologic Agents/)
25. Deprodone.mp.
26. desoximetasone.mp. or exp Desoximetasone/
27. exp Dexamethasone/ or dexamethasone.mp.
28. dichlorisone.mp.
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29. diflorasone.mp.
30. exp Diflucortolone/ or diflucortolone.mp.
31. Difluprednate.mp.
32. fluclorolone.mp.
33. Flucloronide.mp.
34. Fludrocortisone.mp.
35. fludroxycortide.mp.
36. (flumetasone or flumethasone).mp.
37. exp Flumethasone/
38. fluocinolone.mp.
39. fluocinonide.mp. or exp Fluocinonide/
40. fluocortin.mp.
41. exp Fluocortolone/
42. fluocortolone.mp.
43. Fluorometholone.mp.
44. fluprednidene.mp.
45. flurandrenolide.mp.
46. flurandrenolone.mp. or exp Flurandrenolone/
47. fluticasone.mp.
48. halcinonide.mp. or exp Halcinonide/
49. halobetasol.mp.
50. halometasone.mp.
51. exp Hydrocortisone/
52. cortisol.ti,ab. and (exp Administration, Topical/ or exp Ointments/ or Dermatologic Agents/)
53. hydrocortisone$.mp.
54. (masipredone or Mazipredone).mp.
55. exp Methylprednisolone/
56. methylprednisolone.mp.
57. mometasone.mp.
58. prednicarbat$.mp.
59. exp Prednisolone/
60. (Prednisolone or prednisone).mp.
61. ulobetasol.mp.
62. triamcinolone.mp. or exp Triamcinolone/
63. exp Adrenal Cortex Hormones/ and (exp Administration, Topical/ or exp Ointments/ or Dermatologic Agents/)
64. exp Glucocorticoids/ and (exp Administration, Topical/ or exp Ointments/ or Dermatologic Agents/)
65. or/8-64
66. randomized controlled trial.pt.
67. controlled clinical trial.pt.
68. randomized.ab.
69. placebo.ab.
70. clinical trials as topic.sh.
71. randomly.ab.
72. trial.ti.
73. 66 or 67 or 68 or 69 or 70 or 71 or 72
74. exp animals/ not humans.sh.
75. 73 not 74
76. 7 and 65 and 75
[Lines 66-75: Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity- and precision-
maximizing version (2008 revision)]
13Different strategies for using topical corticosteroids in people with eczema (Protocol)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C O N T R I B U T I O N S O F A U T H O R S
JRC was the contact person with the editorial base.
JRC, EA, and JH co-ordinated the contributions from the co-authors and wrote the final draft of the protocol.
JRC, EA, JH, and BC worked on the Methods section.
JRC, EA, and JH drafted the clinical sections of the Background and responded to the clinical comments of the referees.
JRC, EA, JH, and BC responded to the methodology and statistics comments of the referees.
All authors contributed to writing the protocol.
AR and AA were the consumer co-authors and checked the protocol for readability and clarity. They also ensured that the outcomes
are relevant to consumers.
D E C L A R A T I O N S O F I N T E R E S T
JRC: member of the HOME executive, ECO co-applicant
EA: none known
JH: none known
KST: member of the HOME executive, ECO joint-lead-applicant
MS: none known
HCW: Chair of the HOME executive, Developed the POEM scale, ECO co-applicant
BC: none known
SL: ECO co-applicant, Honorarium Thorton Ross - lecture
MR: funded by National Institute for Health Research (NIHR) Post-doctoral Fellowship (PDF-2014-07-013)
SML: funded by Wellcome Senior Clinical fellowship
CML: none known.
SP: Merck, FDC & GSK-Stiefel (who produce products that may be used in atopic eczema) are advertisers in the Indian Journal of
Dermatology, Venereology & Leprology of which I am the Editor-in-Chief.
PC: none known.
AR: ECO co-applicant
AA: ECO co-applicant
IM: ECO co-applicant
14Different strategies for using topical corticosteroids in people with eczema (Protocol)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Disclaimer
This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Skin
Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews
Programme, NIHR, NHS or the Department of Health.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• The National Institute for Health Research (NIHR), UK.
The NIHR, UK, is the largest single funder of the Cochrane Skin Group.
• NIHR, UK.
This review forms part of a body of work funded by the National Institute for Health Research (NIHR) Programme Grants for
Applied Research (grant no: RP-PG-0216-20007) to develop an online behavioural intervention to support self-care of atopic eczema
in children, adolescents and young adults and the findings will contribute to development of the intervention by providing data on
the best and safest ways to use topical corticosteroids.
15Different strategies for using topical corticosteroids in people with eczema (Protocol)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
